Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.
For more information on how to use this blog click here, the HCV drug pipeline click here, and for more information on HCV clinical trials click here
Drugs in Development / Clinical Trials—Updated September 17, 2014
Monday, September 22, 2014
In Malaysia, it is estimated that as at 2010 the HCV infections were at 397,515. According to a report in The Star dated June 8, 2014, the present rate of infection is likely to be much higher as often many infected with hepatitis C are not aware of their status.
In this context, new oral medicines bring significant new hope for many people infected with the Hepatitis C virus with its better cure rates and lesser side effects. However, hopes for universal affordable curable treatment were dashed with Gilead’s announcement on Sept 15 of a voluntary licence on two direct-acting oral antivirals (DAAs) used to treat HCV infections, sofosbuvir (Sovaldi®) and ledipasvir.
Saturday, September 20, 2014
The new hepatitis C pill by Gilead Sciences has arrived in Egypt at more than 99 percent discount to the US price.
According to the Health Minister, the Daqahliya governorate has seen the highest number of patients registered, at 21,803. Meanwhile, 18,640 registered in Sharqiya and 16,212 registered in Cairo. All those who register will undergo a free preliminary examination at their nearest registered centre, announced the Minister.
Comments by Alan Franciscus, Editor-in-Chief, HCV Advocate
This is remarkable and much needed in Egypt because of high rate of co-infections (HIV and schistosomiasis) that can lead to faster disease progression. We will be kicking off a new series of fact sheets next month titled "HCV Around the World." We decided on Egypt as our first in the series since it has the highest percentage of HCV and it is one of the poorest countries. Alan
Friday, September 19, 2014
Research published Wednesday in Science Translational Medicine supports what scientists already suspected about the punch certain antibodies can deliver to hepatitis C.
Led by Dr. Ype P. de Jong, a gastroenterologist, professor, and attending physician at Cornell University, scientists showed that in cell cultures and in mice these broadly neutralizing antibodies interrupt the cycle of hepatitis C (HCV) infection.
“The largest takeaway is that HCV can rapidly be cured if the infectious cycle is interrupted,” de Jong told Healthline. “This goes against the current dogma that HCV is not [damaging] to the liver cells and happily replicates in the liver without killing either its host cell or being cleared by its host cell.”
Newswise — ST. LOUIS – After the success of a new drug treatment in adults with hepatitis C infection, a Saint Louis University pediatric researcher is testing the safety and efficacy of the medications in children.
Part of a multi-center clinical study, SLU is the only center in the region that will examine a combination of two drugs – Sofosbuvir and Ribavirin – in children between ages 3 and 17. The aim of the study is to cure the infection with few side effects.
The current approach to treat the hepatitis C infection is with interferon shots combined with Ribavirin, a therapy that takes about six to 12 months and also causes many side effects including, flu-like symptoms and depression.
Thursday, September 18, 2014
The new law will allow doctors and nurse practitioners to authorize registered nurses to administer the test. Previously, nurses could only screen for hepatitis C if a physician gave them written permission for a specific patient.
"It may seem like not a big hurdle in a small, family practitioner office," said Assemblyman Ken Zebrowski, D-New City, Rockland County, who sponsored the bill. "But in large health care settings, in hospitals and things like that, there seemed to be a barrier. There was a delay."